CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Dapagliflozin for treating chronic heart failure with reduced ejection fraction Association of Cardiovascular Disease With Respiratory Disease A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced AIM2-driven inflammasome activation in heart failure Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review

Review ArticleVolume 73, Issue 17, May 2019

JOURNAL:J Am Coll Cardiol. Article Link

Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review

M.G.D Buono, R Arena, BA Borlaug et al. Keywords: cardiorespiratory fitness; HFrEF; HFpEF; exercise capacity; comorbidities

ABSTRACT


Exercise intolerance is the cardinal symptom of heart failure (HF) and is of crucial relevance, because it is associated with a poor quality of life and increased mortality. While impaired cardiac reserve is considered to be central in HF, reduced exercise and functional capacity are the result of key patient characteristics and multisystem dysfunction, including aging, impaired pulmonary reserve, as well as peripheral and respiratory skeletal muscle dysfunction. We herein review the different modalities to quantify exercise intolerance, the pathophysiology of HF, and comorbid conditions as they lead to reductions in exercise and functional capacity, highlighting the fact that distinct causes may coexist and variably contribute to exercise intolerance in patients with HF.